Melanoma | Topics

Positive Efficacy Data Found With Lifileucel TIL Therapy for Pretreated Advanced Melanoma
April 11, 2021

Lifileucel (LN-144), the tumor-infiltrating lymphocyte therapy, showed a positive objective response rate with the median duration of response not yet reached after more than 28 months of follow-up in patients with advanced melanoma.

Adjuvant Nivolumab Plus Ipilimumab Combo For Late-Stage Melanoma Did Not Meet RFS End Point
April 11, 2021

The combination adjuvant treatment of ipilimumab plus nivolumab did not meet the dual primary endpoints of the phase 3 CheckMate-915 trial, failing to improve relapse-free survival in the intent-to-treat and PD-L1 of less than 1% populations.

Tebentafusp Improves OS in Frontline Setting of Metastatic Uveal Melanoma
April 10, 2021

Frontline treatment with tebentafusp significantly improved overall survival in patients with metastatic uveal melanoma, according to data from the phase 3 IMCgp100-202 trial.